SCHEMBL7148527

SCHEMBL7148527

CNCC(=O)N(C)c1ccc(COC(C)(C)C)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPIB P23284 2/20 0.40
KDM4E B2RXH2 2/20 0.37
ALDH1A1 P00352 2/20 0.37
HPGD P15428 2/20 0.37
NPC1 O15118 1/20 0.37
GAA P10253 1/20 0.37
TSHR P16473 1/20 0.37
MAPK1 P28482 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
HSD17B10 Q99714 1/20 0.37
NOTUM Q6P988 1/20 0.35
MLYCD O95822 2/20 0.35
THRB P10828 1/20 0.35
NR1H4 Q96RI1 1/20 0.35
TRPV1 Q8NER1 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
MAPT P10636 1/20 0.33
GPR88 Q9GZN0 1/20 0.33
DRD4 P21917 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7148520 0.85 PPIB (0.38) PPIBKDM4EALDH1A1HPGDNPC1
SCHEMBL7137957 0.84 PPIB (0.45) PPIBKDM4EALDH1A1HPGDNPC1
SCHEMBL7148523 0.83 PPIB (0.38) PPIBKDM4EALDH1A1HPGDNPC1
SCHEMBL7142708 0.81 PPIB (0.37) PPIBKDM4EALDH1A1HPGDNPC1
SCHEMBL7141053 0.79 CA1 (0.46) PPIBALDH1A1TSHRMAPK1MLYCD
SCHEMBL22567471 0.77 NR1H4 (0.48) ALDH1A1NPC1TSHRSMN1; SMN2HSD17B10
SCHEMBL8353503 0.75 THRB (0.49) PPIBKDM4EALDH1A1GAATSHR
SCHEMBL24233024 0.73 POLQ (0.46) KDM4EALDH1A1GAAHSD17B10MAPT
SCHEMBL7508139 0.73 DRD4 (0.47) ALDH1A1NPC1TSHRSMN1; SMN2HSD17B10
SCHEMBL1821412 0.73 PPIB (0.52) PPIBKDM4EALDH1A1SMN1; SMN2DRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1303485-A1 PYRROLIDINE DERIVATIVES AS INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME F. HOFFMANN-LA ROCHE AG (CH) 2003-04-23 EP disclosed
US-6541638-B2 (2S,4S)-1-(4-Mercapto-1-(naphthalene-2-sulfonyl)-pyrrolidine-2 -carbonyl)-piperidine-4-carboxylic acid ethyl ester for example; zinc protease inhibitors; for treating diseases associated with vasoconstriction HOFFMAN-LA ROCHE INC. 2003-04-01 US disclosed
US-20020049243-A1 Pyrrolidine derivatives HOFFMANN-LA ROCHE INC. 2002-04-25 US disclosed
WO-2002006222-A1 PYRROLIDINE DERIVATIVES AS INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME F. HOFFMANN-LA ROCHE AG (CH) 2002-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020049243-A1 Pyrrolidine derivatives PREP, PEPD, DNPEP PPIB 304/4885KDM4E 1295/4885ALDH1A1 767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.